Xilio Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Waltham, MA
XLO chart
What traders are saying about $XLO
Latest postsXilio Therapeutics, Inc. news
- Xilio Therapeutics, Inc. (XLO) stock price, news, quote and history
Yahoo Finance UK ·
- Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
Yahoo Finance ·
- Xilio Therapeutics Announces First Patient Dosed in Phase
GlobeNewswire ·
- An experimental lung cancer drug has reached its first patient. Xilio expects initial results in the fourth quarter of 2027.
Stock Titan ·
- Xilio Therapeutics, Inc. Estimates – NASDAQ:XLO
TradingView ·
- Raymond James initiates Xilio Therapeutics stock with outperform rating
Investing.com ·
- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Yahoo Finance ·
- Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Yahoo Finance ·
- 3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
Yahoo Finance ·
- Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Yahoo Finance ·
- Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Yahoo Finance ·
Xilio Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $43.8M | $6.3M | – | – |
| Net income | -$35.0M | -$58.2M | -$76.4M | -$88.2M |
| Diluted EPS | $-4.19 | $-15.24 | $-2.78 | $-3.22 |
| Total assets (year end) | $154.7M | $71.1M | $60.9M | $139.2M |
| Cash and equivalents (year end) | $137.5M | $55.3M | $44.7M | $120.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Xilio Therapeutics, Inc.
- Ticker
- XLO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1840233
Frequently asked questions
What exchange is Xilio Therapeutics, Inc. listed on?
Xilio Therapeutics, Inc. trades on the Nasdaq under the ticker symbol XLO.
What industry is Xilio Therapeutics, Inc. in?
Xilio Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Xilio Therapeutics, Inc. headquartered?
Xilio Therapeutics, Inc.'s business address on file with the SEC is in Waltham, MA.
When does Xilio Therapeutics, Inc.'s fiscal year end?
Xilio Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Xilio Therapeutics, Inc. report?
Xilio Therapeutics, Inc. reported $43.8M in revenue for calendar year 2025, according to its SEC filings.